Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Renal Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1390729
This article is part of the Research Topic Advancements in the Management of Cardio-Renal Syndrome: Pioneering Treatments and Therapeutic Breakthroughs View all 3 articles

Machine learning model for cardiovascular disease prediction in patients with chronic kidney disease

Provisionally accepted
He Zhu He Zhu 1,2*Shen Qiao Shen Qiao 3,4*Delong Zhao Delong Zhao 1*Keyun Wang Keyun Wang 1*Bin Wang Bin Wang 1Yue Niu Yue Niu 1*Shunlai Shang Shunlai Shang 1Zheyi Dong Zheyi Dong 1WeiGuang Zhang WeiGuang Zhang 1Ying Zheng Ying Zheng 1*Xiangmei Chen Xiangmei Chen 1*
  • 1 Key Laboratory of Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Beijing, China
  • 2 School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, China
  • 3 Division of Medical Innovation Research, Chinese PLA General Hospital, Beijing, China
  • 4 Medical Big Data Center, Chinese PLA General Hospital, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Introduction: Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD). This study aimed to develop CVD risk prediction models using machine learning to support clinical decision making and improve patient prognosis. Methods: Electronic medical records from patients with CKD at a single center from 2015 to 2020 were used to develop machine learning models for the prediction of CVD. Least absolute shrinkage and selection operator (LASSO) regression was used to select important features predicting the risk of developing CVD. Seven machine learning classification algorithms were used to build models, which were evaluated by receiver operating characteristic curves, accuracy, sensitivity, specificity, and F1-score, and Shapley Additive explanations was used to interpret the model results. CVD was defined as composite cardiovascular events including coronary heart disease (coronary artery disease, myocardial infarction, angina pectoris, and coronary artery revascularization), cerebrovascular disease (hemorrhagic stroke and ischemic stroke), deaths from all causes (cardiovascular deaths, non-cardiovascular deaths, unknown cause of death), congestive heart failure, and peripheral artery disease (aortic aneurysm, aortic or other peripheral arterial revascularization). A cardiovascular event was a composite outcome of multiple cardiovascular events, as determined by reviewing medical records. Results: This study included 8,894 patients with CKD, with a composite CVD event incidence of 25.9%; a total of 2,304 patients reached this outcome. LASSO regression identified eight important features for predicting the risk of CKD developing into CVD: age, history of hypertension, sex, antiplatelet drugs, high-density lipoprotein, sodium ions, 24-h urinary protein, and estimated glomerular filtration rate. The model developed using Extreme Gradient Boosting in the test set had an area under the curve of 0.89, outperforming the other models, indicating that it had the best CVD predictive performance. Conclusion: This study established a CVD risk prediction model for patients with CKD, based on routine clinical diagnostic and treatment data, with good predictive accuracy. This model is expected to provide a scientific basis for the management and treatment of patients with CKD.

    Keywords: Chronic Kidney Disease, cardiovascular disease, Electronic Medical Records, Prediction model, machine learning

    Received: 23 Feb 2024; Accepted: 08 May 2024.

    Copyright: © 2024 Zhu, Qiao, Zhao, Wang, Wang, Niu, Shang, Dong, Zhang, Zheng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    He Zhu, Key Laboratory of Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Beijing, China
    Shen Qiao, Division of Medical Innovation Research, Chinese PLA General Hospital, Beijing, 100853, China
    Delong Zhao, Key Laboratory of Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Beijing, China
    Keyun Wang, Key Laboratory of Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Beijing, China
    Yue Niu, Key Laboratory of Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Beijing, China
    Ying Zheng, Key Laboratory of Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Beijing, China
    Xiangmei Chen, Key Laboratory of Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.